Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Novartis Foundation Symposium
|
November 12, 2003
Notch signalling in the peripheral immune system
Margaret J Dallman, Brian Champion, Jonathan R Lamb
BMC Cell Biology
|
March 2, 2006
Cellular Notch responsiveness is defined by phosphoinositide 3-kinase-dependent signals
Grahame McKenzie, George Ward, Yvette Stallwood, et al.
Vaccines
|
January 26, 2016
Anti-IgE Qb-VLP Conjugate Vaccine Self-Adjuvants through Activation of TLR7
Bassel Akache, Risini D Weeratna, Aparna Deora, et al.
Cells
|
April 9, 2014
CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization
Rebecca J Platt, Tansi Khodai, Tim J Townend, et al.
Molecular Therapy Oncolytics
|
January 1, 2020
Calcium Influx Caused by ER Stress Inducers Enhances Oncolytic Adenovirus Enadenotucirev Replication and Killing through PKCα Activation
William K Taverner, Egon J Jacobus, John Christianson, et al.
Molecular Therapy Oncolytics
|
May 9, 2017
Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus
Sam Illingworth, Ying Di, Maxine Bauzon, et al.
Journal for Immunotherapy of Cancer
|
June 15, 2018
Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells
Janet Lei, Egon J Jacobus, William K Taverner, et al.
Journal for Immunotherapy of Cancer
|
December 11, 2021
Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial
Victor Moreno, Maria-Pilar Barretina-Ginesta, Jesús García-Donas, et al.
Journal for Immunotherapy of Cancer
|
January 30, 2019
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)
Jean-Pascal Machiels, Ramon Salazar, Sylvie Rottey, et al.
Journal for Immunotherapy of Cancer
|
September 20, 2017
Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection
Rocio Garcia-Carbonero, Ramon Salazar, Ignacio Duran, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Novartis Foundation Symposium
|
November 12, 2003
Notch signalling in the peripheral immune system
Margaret J Dallman, Brian Champion, Jonathan R Lamb
BMC Cell Biology
|
March 2, 2006
Cellular Notch responsiveness is defined by phosphoinositide 3-kinase-dependent signals
Grahame McKenzie, George Ward, Yvette Stallwood, et al.
Vaccines
|
January 26, 2016
Anti-IgE Qb-VLP Conjugate Vaccine Self-Adjuvants through Activation of TLR7
Bassel Akache, Risini D Weeratna, Aparna Deora, et al.
Cells
|
April 9, 2014
CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization
Rebecca J Platt, Tansi Khodai, Tim J Townend, et al.
Molecular Therapy Oncolytics
|
January 1, 2020
Calcium Influx Caused by ER Stress Inducers Enhances Oncolytic Adenovirus Enadenotucirev Replication and Killing through PKCα Activation
William K Taverner, Egon J Jacobus, John Christianson, et al.
Molecular Therapy Oncolytics
|
May 9, 2017
Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus
Sam Illingworth, Ying Di, Maxine Bauzon, et al.
Journal for Immunotherapy of Cancer
|
June 15, 2018
Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells
Janet Lei, Egon J Jacobus, William K Taverner, et al.
Journal for Immunotherapy of Cancer
|
December 11, 2021
Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial
Victor Moreno, Maria-Pilar Barretina-Ginesta, Jesús García-Donas, et al.
Journal for Immunotherapy of Cancer
|
January 30, 2019
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)
Jean-Pascal Machiels, Ramon Salazar, Sylvie Rottey, et al.
Journal for Immunotherapy of Cancer
|
September 20, 2017
Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection
Rocio Garcia-Carbonero, Ramon Salazar, Ignacio Duran, et al.
Page
of 2